0.73
-0.0019(-0.26%)
Currency In USD
| Previous Close | 0.73 |
| Open | 0.7 |
| Day High | 0.73 |
| Day Low | 0.7 |
| 52-Week High | 7.5 |
| 52-Week Low | 0.7 |
| Volume | 17,094 |
| Average Volume | 6.38M |
| Market Cap | 5.45M |
| PE | -0.07 |
| EPS | -10.6 |
| Moving Average 50 Days | 1.03 |
| Moving Average 200 Days | 2.31 |
| Change | -0 |
If you invested $1000 in Pasithea Therapeutics Corp. (KTTA) since IPO date, it would be worth $10.29 as of July 02, 2025 at a share price of $0.733. Whereas If you bought $1000 worth of Pasithea Therapeutics Corp. (KTTA) shares 3 years ago, it would be worth $36.64 as of July 02, 2025 at a share price of $0.733.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
GlobeNewswire Inc.
Jun 11, 2025 11:02 AM GMT
Dr. James Lee of the Francis Crick Institute will help guide development of PAS-004 for ETS2-driven diseases such as inflammatory bowel disease (IBD)MIAMI, June 11, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
GlobeNewswire Inc.
Jun 02, 2025 12:02 PM GMT
-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma, who had progressed after two prior
Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases
GlobeNewswire Inc.
May 20, 2025 11:01 AM GMT
-- Demonstrates PAS-004’s potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis – -- Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into inflammatory